VRDN Q1 2018 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+935.5% YoY

Gross Profit

-$2M-34.1% margin

Operating Income

-$5M-96.6% margin

Net Income

-$5M-97.4% margin

EPS (Diluted)

$-2.64

QoQ Revenue Growth

+301.3%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$790,000

Balance Sheet

Total Assets

$87M

Total Liabilities

$14M

Stockholders' Equity

$73M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$462,000	+935.5%
Gross Profit	-$2M	-$4M	+55.5%
Operating Income	-$5M	-$7M	+33.4%
Net Income	-$5M	-$7M	+33.2%